Potential role of mast cells in hamster cheek pouch carcinogenesis

Oral Oncology

Volumn 44, Issue 11, 2008, Pages 1080-1087

  Aromando, Romina F ^a,b   Pérez, Miguel A ^a   Heber, Elisa M ^b   Trivillin, Verónica A ^b   Tomasi, Víctor H ^a   Schwint, Amanda E ^b   Itoiz, María E ^a,b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b DEPARTAMENTO DE FÍSICA   (Argentina)

Author keywords

BrdU; Carcinogenesis; Hamster cheek pouch; Mast cells; PAR 2; Tryptase

Indexed keywords

TRYPTASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL ACTIVATION; CELL MOTILITY; CELL PROLIFERATION; CHEEK POUCH; CONTROLLED STUDY; DNA SYNTHESIS; ENZYME RELEASE; EPITHELIUM CELL; HAMSTER; IMMUNOHISTOCHEMISTRY; MALE; MAST CELL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELL PROLIFERATION; CHEEK; CRICETINAE; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; FIBROBLAST GROWTH FACTOR 2; MALE; MAST CELLS; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS; TRYPTASES;

EID: 53849100011     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2008.01.016     Document Type: Article

References (26)

1. Yoshii M., Jikuhara A., Mori S., Iwagaki H., Takahashi H., Nishibori M., et al. Mast cell tryptase stimulates DLD-1 carcinoma through prostaglandin and MAP kinase-dependent manners. J Pharmacol Sci 98 (2005) 450-458
2. Sendo T., Suminura T., Itoh Y., Goromaru T., Aki K., Yano T., et al. Involvement of proteinase-activated receptor-2 in mast cell tryptase-induced barrier dysfunction in bovine aortic endothelial cells. Cell Signal 15 (2003) 773-781
3. Nystedt S., Emilsson K., Wahlestedt C., and Sundelin J. Molecular cloning of a potential proteinase activated receptor. Proc Nat Acad Sci USA 91 20 (1994) 9208-9212
4. Bohm S.K., Kong W., Bromme D., Smeeken S.P., Anderson D.C., Connolly A., et al. Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. Biochem J 314 Pt. 3 (1996) 1009-1016
5. Kawabata A., and Kuroda R. Protease activated receptor (PAR), a novel family of G protein-coupled seven trans membrane domain receptors: activation mechanisms and physiological roles. Jap J Pharmacol 82 3 (2000) 171-174
6. Kawabata A., Kuroda R., Nagata N., Kawao N., Masuko T., Nishikawa H., et al. In vivo evidence that protease-activated receptor 1 and 2 modulate gastrointestinal transit in the mouse. Br J Pharmacol 133 8 (2001) 1213-1218
7. Kawabata A., Kinoshita M., Nishikawa H., Kuroda R., Nishida M., Araki H., et al. The protease-activated receptor-2 agonist induces gastric mucus secretion and mucosal cytoprotection. J Clin Invest 107 11 (2001) 1443-1450
8. Kawao N., Sakaguchi Y., Tagome A., Kuroda R., Nishida S., Irimajiri K., et al. Protease-activated receptor-2 (PAR-2) in the rat gastric mucosa: immunolocalization and facilitation of pepsin/pepsinogen secretion. Br J Pharmacol 135 5 (2002) 1292-1296
9. Ducroc R., Bontemps C., Marazova K., Devaud H., Darmoul D., Laburthe M., et al. Trypsin is produced by and activates protease-activated receptor-2 in human cancer colon cells: evidence for new autocrine loop. Life Sci 70 12 (2002) 1359-1367
10. Darmoul D., Marie J.C., Devaud H., Gratio V., and Laburthe M. Initiation of human colon cancer cell proliferation by trypsin acting at protease-activated receptor-2. Br J Cancer 85 5 (2001) 772-779
11. Jikuhara A., Yoshii M., Iwagaki H., Mori S., Nishibori M., Tanaka N., et al. MAP kinase-mediated proliferation of DLD-1 carcinoma by the stimulation of protease-activated receptor 2. Life Sci 73 (2003) 2817-2829
12. Raimondi A., Cabrini R.L., and Itoiz M.E. Ploidy analysis of field cancerization and cancer development in the hamster cheek pouch carcinogenesis model. J Oral Pathol Med 34 4 (2005) 227:31
13. Raimondi A.R., Molinolo A.A., and Itoiz M.E. Fibroblast growth factor-2 expression during experimental oral carcinogenesis. Its possible role in the induction of pre-malignant fibrosis. J Oral Pathol Med 35 (2006) 212-217
14. Pérez M.A., Raimondi A.R., and Itoiz M.E. An experimental model to demonstrate the carcinogenic action of oral chronic traumatic ulcer. J Oral Pathol Med 34 1 (2005) 17-22
15. Irani A.A., Schechter N.M., Craig S.S., Deblois G., and Schwartz L.B. Two types of mast cells that have distinct neutral protease composition. Proc Natl Acad Sci USA 83 (1986) 4464-4468
16. Kambe N., Hiramatsu H., Shimonaka M., Fujino H., Nishiñomori R., Heike T., et al. Development of both human connective tissue-type and mucosal-type mast cells in mice from hematopoietic stem cells with identical distribution pattern to human body. Blood 103 3 (2004) 860-867
17. Feyerabend T.B., Hausser H., Tietz A., Blum C., Hellman L., Straus A.H., et al. Loss of histochemical identity in mast cells lacking carboxipeptidase A. Mol Cell Biol 25 14 (2005) 6199-6210
18. Dimitriadou V., Buzzi M.G., Moskowitz M.A., and Theoharides T.C. Trigeminal sensory fiber stimulation induces morphological changes reflecting secretion in rat dura matter mast cells. Neuroscience 44 (1991) 97-112
19. Shklar G., Eisenberg E., and Flynn E. Immunoenhancing agents and experimental leukoplakia and carcinoma of the hamster buccal pouch. Prog Exp Tumor Res 24 (1979) 269-282
20. Mayrhofer G. Fixation and staining of granules in mucosal mast cells and intraepithelial lymphocytes in the rat jejunum with specimen reference to the relationship between the acid glycosaminoglycans in the two cell types. Histochem J 12 (1989) 513-526
21. Kitamura Y. Heterogeneity of mast cells and phenotypic change between subpopulations. Ann Rev Immunol 7 (1989) 59-76
22. Santos J., Alonso C., Guilarte M., Vicario M., and Malagelada J.R. Targeting mast cells in the treatment of functional gastrointestinal disorders. Curr Opin Pharmacol 6 6 (2006) 541-546
23. Taketo M.M. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 90 (1998) 1609-1620
24. Thun M.J., Henley S.J., and Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94 (2002) 252-266
25. Herendeen J.M., and Lindley C. Use of NSAIDs for the chemoprevention of colorectal cancer. Ann Pharmacother 37 (2003) 1664-1674
26. Subbaramaiah K., and Dannenberg A.J. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24 (2003) 96-102